Higano CS, et al. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. ASCO-GU 2019, abstract 256.
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie